Focus Investment Banking

AUGUST 6, 2023

ESG isn’t just a matter for large, publicly traded companies. Moreover, “a strong ESG proposition can enhance investment returns by allocating capital to more promising and more sustainable opportunities.” This is particularly true if your partners are publicly traded or foreign-owned.

Middle Market 52

Middle Market Business Government Profitability 52

The TRADE

JULY 11, 2023

” The review consists of seven recommendations including the introduction of a Research Platform, which will provide a central facility for the promotion, sourcing and dissemination of research on publicly traded companies – potentially open to all, but in particular, for smaller cap companies.

Asset Management 40

Asset Management Investment Government Capital Market 40

Cooley M&A

JANUARY 25, 2023

Will 2023 see a resurgence of traditional public M&A deals or will macro factors and the looming threat of regulatory review continue to push biotechnology companies down creative paths? It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 22, 2020

And, in general, we saw large pharmaceutical companies deploy substantial amounts of capital in 2019 to acquire innovative biotech companies that are advancing the development of novel therapies for oncology, orphan diseases and other unmet medical needs. Year of the Life Sciences Mega-Deals. billion; and Synthorx’s sale to Sanofi $2.5

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

JANUARY 22, 2021

Time will tell whether SPACs are a fad, and what the impact on the deal market and pending transactions may be if the demand generated by new SPACs begins to outpace the supply of targets who view a SPAC as a compelling source of capital or avenue to the public markets relative to alternatives.

M&A 40

M&A IPO Mergers and Acquisitions Business 40

Cooley M&A

OCTOBER 29, 2020

On September 24, Cooley M&A partner, Garth Osterman, moderated a webinar on the current trend in going public: SPACs! Competition / Variation. Another feature of SPAC 3.0 is the competition among SPACs for potential targets. Revisiting Governance Documentation.

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. These players have looked further afield to add new capabilities and pipeline assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Some sponsors, while unable to present compelling take-private proposals to targets, have deployed capital in private investments in public equity (PIPEs) of public targets, marketing these investments as both a vote of confidence for the incumbent board and much-needed liquidity to help the target weather the downturn.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52